Tuesday, March 17, 2026 10:50:08 AM
Gabagool,
“a single peer-reviewed report” 😶
Fact ✅️:
I cited THREE independently peer-reviewed papers specific to only the DCVax®-L platform technology alone… There are other recent peer-reviewed papers relevant to dendritic cell platforms too, & all DC research is relevant to the development of the field overall…
Dr. Peter Forsyth
Pennies in Action
Moffitt
-Hope we hear some news about collaborations between Dr. Czerniecki at Moffitt & Dr. Kalinski at Pitt!
Moffitt Endeavor Dec 22, 2025
NCT05325632
JAMA Oncology
“They called me Gabagool Research”
AI Fact-Checking
“a single peer-reviewed report” 😶
Fact ✅️:
I cited THREE independently peer-reviewed papers specific to only the DCVax®-L platform technology alone… There are other recent peer-reviewed papers relevant to dendritic cell platforms too, & all DC research is relevant to the development of the field overall…
Dr. Peter Forsyth
Pennies in Action
Moffitt
-Hope we hear some news about collaborations between Dr. Czerniecki at Moffitt & Dr. Kalinski at Pitt!
Moffitt Endeavor Dec 22, 2025
NCT05325632
Intratumoral delivery of dendritic cells combined with anti-HER2 antibodies is safe and effective in altering the tumor microenvironment and inducing dramatic tumor regression prior to chemotherapy in early-stage HER2-positive breast cancer. https://t.co/QgI6ZQfgtq pic.twitter.com/kLMjIDjwXj
— JAMA Oncology (@JAMAOnc) December 5, 2024
JAMA Oncology
“They called me Gabagool Research”
AI Fact-Checking
Bullish
I am a long NWBO shareholder. Views expressed are my own, and I have no affiliation with the company.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
